Immune response to SARS-CoV-2 vaccination among chronic myeloid leukaemia patients on tyrosine kinase inhibitors
Document Type
Article
Publication Date
4-1-2026
Abstract
Introduction: Chronic myeloid leukaemia (CML) patients on tyrosine kinase inhibitors (TKIs) show adequate antibody responses to SARS-CoV-2 vaccination, but T-cell responses remain unclear. This study investigates the overall immune responses in these patients after vaccination. Methods: In this longitudinal study, CML patients on TKIs who received at least 3 doses of the SARS-CoV-2 vaccine were assessed for neutralisation activity against the wild-type (WT) and Omicron variants at multiple time-points: baseline (D0), week 4 (D28), month 6 (M6), and after the booster dose at months 3 (B3), 6 (B6), and 12 (B12). T-cell responses were evaluated at B6 and B12, with comparisons made to healthy controls (HC). Results: Twenty-seven CML patients and 113 HC were included. Neutralising activity against WT was similar across groups at all time points. Fewer CML patients exhibited positive neutralisation against Omicron at B6 (50.0% versus 88.9%, P=0.003), with higher antibody levels in CML patients at D28 and M6, but lower levels at B6 (P< 0.05). T-cell responses were similar between groups at B6 and B12. Conclusion: Neutralising activity against WT and Omicron was similar, with a decline at B6, while T-cell responses were comparable across groups. These findings highlight the importance of continued vaccination in CML patients.
Keywords
chronic myeloid leukemia, COVID-19 vaccine, neutralising antibodies, Omicron variant, vaccine durability
Publication Title
Annals of the Academy of Medicine Singapore
ISSN
0304-4602
DOI
10.47102/annals-acadmedsg.2025368
Recommended Citation
Cheong, Chin Sum; Ng, Leh Ching Diana; Yap, Siew Hwei; Rajasuriar, Reena; Arshad, Normala; Zulhaimi, Nurul Syuhada; Kong, Boon Hong; Sam, I. Ching; Bee, Ping Chong; Kerishnan, Jesinda P.; and Gan, Gin Gin, "Immune response to SARS-CoV-2 vaccination among chronic myeloid leukaemia patients on tyrosine kinase inhibitors" (2026). Research Publications (2026 to 2030). 843.
https://knova.um.edu.my/research_publications_2026_2030/843
Funders
Malaysian Society of Haematology
Volume
55
Issue
4
First Page
179
Last Page
188
Publisher
Academy of Medicine Singapore